BioTuesdays

Category - Markets

Organigram
Markets

AGP starts Organigram at buy; PT $4

Alliance Global Partners initiated coverage of Organigram Holdings (TSX:OGI) with a “buy” rating and price target of $4 (Canadian). The stock closed at $2.11 on July 6. “We view Organigram’s low-cost indoor [cannabis]...

July 7, 2020
Markets

Chardan starts Akero Therapeutics at buy; PT $79

Chardan Capital Markets launched coverage of Akero Therapeutics (NASDAQ:AKRO) with a “buy” rating and $79 price target. The stock closed at $34.96 on July 6. “We expect that Akero’s lead asset, efruxifermin, has...

July 7, 2020
Venus-Concept-Logo
Markets

BTIG starts Venus Concept at buy; PT $7

BTIG initiated coverage of Venus Concept (NASDAQ:VERO) with a “buy” rating and $7 price target. The stock closed at $3.52 on June 2. “It is not an easy time to be an aesthetics device company amidst the COVID-19...

July 6, 2020
AdaptHealth
Markets

SVB Leerink starts AdaptHealth at OP; PT $21

SVB Leerink launched coverage of AdaptHealth (NASDAQ:AHCO) with an “outperform” rating and $21 price target. The stock closed at $16.10 on June 30. Analyst Stephen Tanal writes that AdaptHealth is fast becoming the...

July 1, 2020
Markets

SVB Leerink starts Applied Molecular at OP; PT $32

SVB Leerink initiated coverage of Applied Molecular Transport (NASDAQ:AMTI) with an “outperform” rating and $32 price target. The stock closed at $25.80 on June 29. “We believe Applied’s emerging translocation...

June 30, 2020
Merus Logo
Markets

HCW starts Merus NV at buy; PT $23

H.C. Wainwright launched coverage of Merus NV (NASDAQ:MRUS) with a “buy” rating and $23 price target. The stock closed at $15.80 on June 25. “Given the recent advances in structure-based design, bispecific antibodies...

June 26, 2020
Mersana Therapeutics Logo
Markets

BTIG ups Mersana Therapeutics PT to $32 from $21

BTIG raised its price target for Mersana Therapeutics (NASDAQ:MRSN) to $32 from $21, saying the company’s STING agonist antibody-drug conjugates look compelling on the evolving immunoncology landscape. The stock closed...

June 24, 2020
Brookline Logo
Markets

Brookline boosts life sciences equity research

Brookline Capital Markets added Sally Yanchus and Leah Rush Cann to its life sciences equity research team.  With the addition of Ms. Yanchus and Ms. Cann, Brookline now has three publishing life sciences analysts, as...

June 24, 2020
Markets

HCW starts Aprea Therapeutics at neutral; PT $30

H.C. Wainwright initiated coverage of Aprea Therapeutics (NASDAQ:APRE) with a “neutral” rating and $30 price target. The stock closed at $37.90 on June 19. “We see more downside risk heading into pivotal data,” writes...

June 22, 2020